Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BriaCell Therapeutics ( (TSE:BCT) ) has issued an announcement.
BriaCell Therapeutics has announced that its Phase 3 clinical study for its lead candidate, Bria-IMT, in combination with an immune checkpoint inhibitor, is progressing well with over 160 patients enrolled. The study, which targets metastatic breast cancer, is on track for a topline data readout in the first half of 2026, potentially leading to full approval and marketing authorization if results are positive.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$40.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care.
Average Trading Volume: 3,902
Technical Sentiment Signal: Sell
Current Market Cap: C$29.77M
Learn more about BCT stock on TipRanks’ Stock Analysis page.